Press Releases
Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ 801 in Patients with Early Alzheimer’s Disease
Study to Confirm ALZ-801 Effects on Cognition and Function in High-Risk Patients with APOE4/4 Genotype
Alzheon Partners with Czech Institute of Organic Chemistry and Biochemistry to Develop First Alzheimer’s Diagnostic Assay for Measuring Neurotoxic Beta Amyloid Oligomers in Human Brain
Assay Builds on Alzheon’s Research to Detect and Quantify Soluble Oligomers, and Enhances Phase 2 and Phase 3 Alzheimer’s Studies with Oral ALZ-801.
Alzheon to Present at H.C. Wainwright Global Life Sciences Conference
Dr. Martin Tolar, CEO of Alzheon will Present an Overview of Oral Anti-amyloid ALZ-801 Phase 3 Program at the H.C. Wainwright Global Life Sciences Virtual Conference.
Alzheon CEO Presents Overview of Oral Anti-Amyloid ALZ-801 Phase 3 Program at 9th Neurodegenerative Drug Development Summit
Dr. Martin Tolar to Provide an Update on Alzheon’s ALZ-801 Phase 3 Program and Join Panel Discussion on Current Research in Alzheimer’s Disease.
Alzheon Announces New Research Showing Accelerated Hippocampus Atrophy in APOE4/4 Patients with Early Alzheimer’s Disease
Hippocampus Atrophy and Cortical Thinning Correlate with Cognitive Decline and Show Promise as Biomarkers in Alzheimer’s Treatment and Prevention Clinical Trials.
Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer’s Disease
Study to Evaluate ALZ-801 Effects on Alzheimer’s Biomarkers Associated with Clinical BenefitIncludes Comprehensive Biomarker Assessment to Accelerate Development of ALZ-801 for Alzheimer’s Disease PreventionFacilitates Biomarker-Enabled Indication Expansion [...]